FY2028 Earnings Estimate for Disc Medicine Issued By Wedbush

Disc Medicine, Inc. (NASDAQ:IRON) – Analysts at Wedbush upped their FY2028 earnings per share (EPS) estimates for Disc Medicine in a research note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $7.04 per share for the year, up from their previous forecast of $6.85. Wedbush currently has a “Outperform” rating and a $83.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.15.

Several other research firms have also issued reports on IRON. Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a research note on Tuesday, November 5th. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. Jefferies Financial Group started coverage on Disc Medicine in a research note on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price objective for the company. HC Wainwright increased their target price on shares of Disc Medicine from $70.00 to $118.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Scotiabank boosted their price objective on shares of Disc Medicine from $62.00 to $70.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 5th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $85.80.

Disc Medicine Stock Performance

IRON stock opened at $59.46 on Thursday. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -14.94 and a beta of 0.60. The stock has a fifty day moving average of $51.20 and a 200-day moving average of $44.97. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors have recently bought and sold shares of IRON. Amalgamated Bank raised its holdings in shares of Disc Medicine by 76.9% during the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after acquiring an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after purchasing an additional 337 shares in the last quarter. Quest Partners LLC acquired a new stake in Disc Medicine in the third quarter valued at approximately $131,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine during the 2nd quarter worth $129,000. Finally, Quantbot Technologies LP acquired a new position in shares of Disc Medicine during the 3rd quarter worth about $146,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Disc Medicine

In related news, Director William Richard White sold 7,136 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 7,538 shares of company stock valued at $437,875. 4.24% of the stock is currently owned by insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.